255 related articles for article (PubMed ID: 20065191)
1. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Lo SS; Mumby PB; Norton J; Rychlik K; Smerage J; Kash J; Chew HK; Gaynor ER; Hayes DF; Epstein A; Albain KS
J Clin Oncol; 2010 Apr; 28(10):1671-6. PubMed ID: 20065191
[TBL] [Abstract][Full Text] [Related]
2. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
[TBL] [Abstract][Full Text] [Related]
3. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
4. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
Albanell J; González A; Ruiz-Borrego M; Alba E; García-Saenz JA; Corominas JM; Burgues O; Furio V; Rojo A; Palacios J; Bermejo B; Martínez-García M; Limon ML; Muñoz AS; Martín M; Tusquets I; Rojo F; Colomer R; Faull I; Lluch A
Ann Oncol; 2012 Mar; 23(3):625-631. PubMed ID: 21652577
[TBL] [Abstract][Full Text] [Related]
5. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
[TBL] [Abstract][Full Text] [Related]
6. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
[TBL] [Abstract][Full Text] [Related]
7. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
Eiermann W; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Schneeweiss A; Markmann S; Eggemann H; Hilfrich J; Jackisch C; Witzel I; Eidtmann H; Bachinger A; Hell S; Blohmer J
Ann Oncol; 2013 Mar; 24(3):618-24. PubMed ID: 23136233
[TBL] [Abstract][Full Text] [Related]
8. Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study.
LeVasseur N; Sun J; Fenton D; Baxter S; Chan A; Roberts S; Feng X; Lohrisch C; Gelmon K; Shenkier T; Chia SK
Clin Breast Cancer; 2022 Jan; 22(1):e74-e79. PubMed ID: 34690081
[TBL] [Abstract][Full Text] [Related]
9. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
[TBL] [Abstract][Full Text] [Related]
10. The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings.
Alkushi A; Omair A; Masuadi E; Alamri G; Abusanad A; Abdelhafiez N; Mohamed AE; Abulkhair O
Cureus; 2021 Feb; 13(2):e13298. PubMed ID: 33738150
[TBL] [Abstract][Full Text] [Related]
11. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
[No Abstract] [Full Text] [Related]
12. Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec.
Hassan S; Younan R; Patocskai E; Provencher L; Poirier B; Sideris L; Dubé P; Mihalcioiu C; Chabot-Blanchet M; Guertin MC; Boileau JF; Robidoux A
Oncologist; 2022 Oct; 27(10):822-831. PubMed ID: 35830543
[TBL] [Abstract][Full Text] [Related]
13. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
de Boer RH; Baker C; Speakman D; Chao CY; Yoshizawa C; Mann GB
Med J Aust; 2013 Aug; 199(3):205-8. PubMed ID: 23909545
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Pestalozzi BC; Tausch C; Dedes KJ; Rochlitz C; Zimmermann S; von Moos R; Winterhalder R; Ruhstaller T; Mueller A; Buser K; Borner M; Novak U; Nussbaum CU; Seifert B; Bigler M; Bize V; Vilei SB; Rageth C; Aebi S;
BMC Cancer; 2017 Apr; 17(1):265. PubMed ID: 28407750
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.
Manders JB; Kuerer HM; Smith BD; McCluskey C; Farrar WB; Frazier TG; Li L; Leonard CE; Carter DL; Chawla S; Medeiros LE; Guenther JM; Castellini LE; Buchholz DJ; Mamounas EP; Wapnir IL; Horst KC; Chagpar A; Evans SB; Riker AI; Vali FS; Solin LJ; Jablon L; Recht A; Sharma R; Lu R; Sing AP; Hwang ES; White J;
Ann Surg Oncol; 2017 Mar; 24(3):660-668. PubMed ID: 27704370
[TBL] [Abstract][Full Text] [Related]
16. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
17. Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer.
Zeng Y; Gao W; Lin L; Chen X; Shen K
J Geriatr Oncol; 2020 Jun; 11(5):843-849. PubMed ID: 31704037
[TBL] [Abstract][Full Text] [Related]
18. The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.
Geffen DB; Abu-Ghanem S; Sion-Vardy N; Braunstein R; Tokar M; Ariad S; Delgado B; Bayme M; Koretz M
Ann Oncol; 2011 Nov; 22(11):2381-2386. PubMed ID: 21363879
[TBL] [Abstract][Full Text] [Related]
19. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer.
Yamauchi H; Nakagawa C; Takei H; Chao C; Yoshizawa C; Yagata H; Yoshida A; Hayashi N; Hell S; Nakamura S
Clin Breast Cancer; 2014 Jun; 14(3):191-7. PubMed ID: 24321102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
